INIS
cancer
100%
patients
96%
cost
79%
lungs
48%
lung cells
46%
therapy
41%
biological markers
35%
immunotherapy
33%
implementation
32%
netherlands
28%
values
25%
reviews
21%
evaluation
20%
comparative evaluations
18%
levels
17%
budgets
16%
technology assessment
16%
validation
16%
lifetime
16%
death
13%
gain
12%
testing
12%
utilities
12%
prices
12%
tumors
11%
modeling
11%
metastases
10%
mutations
10%
ligands
10%
genetics
9%
Keyphrases
Whole Genome Sequencing
80%
Cost-effectiveness
42%
Targeted Therapy
35%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
33%
Targeted Immunotherapy
22%
Non-squamous Non-small Cell Lung Cancer
22%
Netherlands
21%
Early Cost-effectiveness
19%
Decision Model
19%
Clinical Diagnostic Tests
17%
Treatment Selection
17%
Lung Cancer
16%
Randomized Controlled Trial
16%
Non-small Cell Lung Cancer Patients
16%
Overall Survival
16%
Budget Impact
16%
Lung Cancer Treatment
16%
Early Technology Assessment
16%
Oncology
16%
Personalized Oncology
16%
Cost Budget
16%
Programmed Death-ligand 1 (PD-L1)
16%
Tumor mutation Burden
14%
Standard of Care
13%
Molecular Diagnostics
9%
Unweighting
9%
Quality-adjusted Life Years
9%
Survival Benefit
9%
Net Monetary Benefit
8%
Metastatic Non-small Cell Lung Cancer
8%
Medicine and Dentistry
Whole Genome Sequencing
64%
Cost-Effectiveness Analysis
40%
Oncology
32%
Lung Cancer
32%
Targeted Therapy
32%
Immunotherapy
29%
Non Small Cell Lung Cancer
22%
Biological Marker
21%
Health Care Cost
20%
Lifespan
16%
Systematic Review
16%
Technology Assessment
16%
Overall Survival
16%
Programmed Death 1 Ligand 1
11%
Tumor Mutation Burden
9%
Base
7%
Quality Adjusted Life Year
6%
